Compare EVC & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVC | PEPG |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 288.4M | 317.6M |
| IPO Year | 2000 | 2022 |
| Metric | EVC | PEPG |
|---|---|---|
| Price | $3.15 | $5.45 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $10.80 |
| AVG Volume (30 Days) | 234.7K | ★ 711.8K |
| Earning Date | 03-05-2026 | 02-23-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $420,178,000.00 | N/A |
| Revenue This Year | $64.06 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.96 | N/A |
| 52 Week Low | $1.58 | $0.88 |
| 52 Week High | $3.44 | $7.80 |
| Indicator | EVC | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 52.40 | 47.69 |
| Support Level | $3.15 | $5.19 |
| Resistance Level | $3.35 | $6.20 |
| Average True Range (ATR) | 0.12 | 0.55 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 44.32 | 26.40 |
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.